All Oncology News

The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine showed encouraging activity and minimal additional toxicity in the treatment of patients with advanced pancreatic adenocarcinoma.

High breast density surpasses other known risk factors for developing breast cancer, including family history of the disease, personal history of benign lesions, and later-in-life childbirth, according to the results of a study published in JAMA Oncology.

Researchers at the University of Wisconsin School of Medicine and Public Health have found that removing a specific type of collagen can dramatically reduce the growth of one form of breast cancer.

In a large-scale study published today in the journal Obstetrics and Gynecology, researchers found that nearly half of women from racial minorities receive cervical-cancer care that doesn’t meet national standards.

The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious diseases, and vaccines, announces the appointment of Joseph M. Salvino, PhD, as professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Institute’s Molecular Screening Facility.

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

The findings from the phase II study of intermittent sunitinib in patients with previously untreated metastatic renal cell carcinoma demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.

Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.

Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.

Harold H. Tara, Jr., MD, has been appointed Medical Director of the Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, Connecticut. Dr. Tara has been a member of the Yale community for 20 years and his leadership will ensure that the centers continue to offer patients the best care available, along with the latest treatment options through clinical trials.

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

The addition of hormonal therapy to radiation treatment following surgery significantly improved survival in patients with recurrent prostate cancer, according to the results of a study published in The New England Journal of Medicine.

Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.

H. Jack West, MD, discusses the benefits of EGFR tyrosine kinase inhibitors in non–small cell lung cancer, challenges with determining optimal sequencing, and potential combinations on the horizon.

Melanie E. Royce, MD, PhD, discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor.

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Ribociclib, an orally bioavailable, selective cyclin-dependent kinase 4/6 inhibitor, demonstrated similar clinical benefits and safety profiles for both elderly and younger patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer.

The FDA has granted an accelerated approval to nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Henry M. Kuerer, MD, PhD, discusses surgical advancements in the field of breast cancer and the goals of a phase II single-center trial and how it could impact these exceptional responders.

Welela Tereffe, MD, discusses the current state of radiation therapy in breast cancer and the importance of a multidisciplinary approach.

A new trend in the way pharmacy benefit managers are collecting fees from pharmacy providers is driving up drug costs, gouging point-of-sale pharmacy operations, and playing havoc with spending at CMS, according to reports from CMS and the Community Oncology Alliance.

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma, according to results reported at the 19th European Cancer Congress.

The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.

Treatment with nanoparticle albumin-bound nab-paclitaxel showed encouraging activity across different subgroups of patients with breast cancer, according to the results of a meta-analysis of several clinical trials.